FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045552185> ?p ?o ?g. }

• W2045552185 endingPage "1028" @default.
• W2045552185 startingPage "1013" @default.
• W2045552185 abstract "Abstract An open-label, multicenter, uncontrolled clinical trial was conducted to assess the efficacy and tolerability of fluvastatin, the first hydroxymethylglutaryl-coenzyme A reductase synthetic inhibitor in the treatment of primary hypercholesterolemia in patients with or without coronary artery disease (CAD) risk factors. This trial was conducted in 2566 men and women 18 years of age or older who received the study medication for at least 12 weeks. Following a minimum of 4 weeks on a low-fat diet (National Cholesterol Education Program), eligible patients took one capsule of fluvastatin 20 mg/d orally, in the evening, during the first 6 weeks and 20 or 40 mg/d (1 or 2 20-mg capsules), in the evening, during the remainder of the trial. Overall, patients had the following risk factors: arterial hypertension, 65.4%; family history of CAD, 54.9%; obesity; 47.9%; nicotine addiction, 34.9%; diabetes, 18.1%; total cholesterol (TC) levels ⩾300 mg/dL, 43.2%; CAD, 17.9%; and peripheral vascular disease, 9.4%. Patients were divided into two groups depending on the initial TC levels. The first group was composed of 1451 patients with mild-to-moderate hypercholesterolemia (TC, 200 to 299 mg/dL); the second group included 1115 patients with severe hypercholesterolemia (TC, ⩾300 mg/dL). The results showed a 22.41% decrease in TC levels in the first group and a 30.94% decrease in the second group. At the end of the study, low-density lipoprotein cholesterol levels decreased by 26.15% and 32.63% in the first and second groups, respectively. High-density lipoprotein cholesterol levels increased by 8.94% in the mild-to-moderate hypercholesterolemia group and by 9.22% in the severe hypercholesterolemia group. Only 9.3% of the patients in the first group and 16.4% of the patients in the second group required an increase from 20 mg/d to 40 mg/d of fluvastatin after the first 6 weeks of treatment. Fluvastatin was well tolerated, with gastrointestinal disorders the most frequent adverse event observed (4.68%). No myopathies were reported. These study results, which are similar to those from other international trials with fluvastatin published to date, show that it is an effective and well-tolerated treatment for hypercholesterolemia." @default.
• W2045552185 created "2016-06-24" @default.
• W2045552185 creator A5063587299 @default.
• W2045552185 creator A5078914838 @default.
• W2045552185 date "1997-12-01" @default.
• W2045552185 modified "2023-09-27" @default.
• W2045552185 title "Argentine multicenter evaluation of fluvastatin in the treatment of patients with hypercholesterolemia" @default.
• W2045552185 cites W1535876373 @default.
• W2045552185 cites W2012940491 @default.
• W2045552185 cites W2026888128 @default.
• W2045552185 cites W2044912303 @default.
• W2045552185 cites W2052048264 @default.
• W2045552185 cites W2057004557 @default.
• W2045552185 cites W2060048165 @default.
• W2045552185 cites W2069575574 @default.
• W2045552185 cites W2110431176 @default.
• W2045552185 cites W2110975084 @default.
• W2045552185 cites W2118310760 @default.
• W2045552185 cites W2123801185 @default.
• W2045552185 cites W4255468399 @default.
• W2045552185 doi "https://doi.org/10.1016/s0011-393x(97)80068-9" @default.
• W2045552185 hasPublicationYear "1997" @default.
• W2045552185 type Work @default.
• W2045552185 sameAs 2045552185 @default.
• W2045552185 citedByCount "3" @default.
• W2045552185 countsByYear W20455521852018 @default.
• W2045552185 crossrefType "journal-article" @default.
• W2045552185 hasAuthorship W2045552185A5063587299 @default.
• W2045552185 hasAuthorship W2045552185A5078914838 @default.
• W2045552185 hasConcept C126322002 @default.
• W2045552185 hasConcept C168563851 @default.
• W2045552185 hasConcept C2776329913 @default.
• W2045552185 hasConcept C2778163477 @default.
• W2045552185 hasConcept C2778417548 @default.
• W2045552185 hasConcept C2779120738 @default.
• W2045552185 hasConcept C2992435398 @default.
• W2045552185 hasConcept C71924100 @default.
• W2045552185 hasConceptScore W2045552185C126322002 @default.
• W2045552185 hasConceptScore W2045552185C168563851 @default.
• W2045552185 hasConceptScore W2045552185C2776329913 @default.
• W2045552185 hasConceptScore W2045552185C2778163477 @default.
• W2045552185 hasConceptScore W2045552185C2778417548 @default.
• W2045552185 hasConceptScore W2045552185C2779120738 @default.
• W2045552185 hasConceptScore W2045552185C2992435398 @default.
• W2045552185 hasConceptScore W2045552185C71924100 @default.
• W2045552185 hasIssue "12" @default.
• W2045552185 hasLocation W20455521851 @default.
• W2045552185 hasOpenAccess W2045552185 @default.
• W2045552185 hasPrimaryLocation W20455521851 @default.
• W2045552185 hasRelatedWork W2008410891 @default.
• W2045552185 hasRelatedWork W2014632515 @default.
• W2045552185 hasRelatedWork W2057216321 @default.
• W2045552185 hasRelatedWork W2060075539 @default.
• W2045552185 hasRelatedWork W2083779424 @default.
• W2045552185 hasRelatedWork W2762542743 @default.
• W2045552185 hasRelatedWork W2899136883 @default.
• W2045552185 hasRelatedWork W4234055013 @default.
• W2045552185 hasRelatedWork W4242174001 @default.
• W2045552185 hasRelatedWork W4254616694 @default.
• W2045552185 hasVolume "58" @default.
• W2045552185 isParatext "false" @default.
• W2045552185 isRetracted "false" @default.
• W2045552185 magId "2045552185" @default.
• W2045552185 workType "article" @default.